{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:16:30Z","timestamp":1789067790498,"version":"build-2803163510"},"reference-count":67,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Clinically meaningful improvement in the Sino\u2010Nasal Outcome Test\u201022 (SNOT\u201022) was observed in patients with severe, eosinophilic asthma, and nasal polyposis (NP) treated with benralizumab in the ANDHI trial. A\n                      <jats:italic>post hoc<\/jats:italic>\n                      assessment of the effects of benralizumab on SNOT\u201022 response and asthma efficacy measures in these patients was conducted for further characterization of the efficacy and safety of benralizumab for patients with severe asthma and NP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Adults with severe, eosinophilic asthma who had experienced \u22652 prior\u2010year exacerbations despite high\u2010dosage inhaled corticosteroid plus additional controller[s] were randomized to 24\u00a0weeks of benralizumab or placebo. Patients with physician\u2010diagnosed chronic rhinosinusitis with NP of any severity ongoing at baseline who consented to participate were included in the current ANDHI NP substudy population. Effect on NP symptoms was assessed by the SNOT\u201022, with an improvement of at least 8.9 defined as clinically significant (responder). Effects on chronic asthma outcomes were assessed by means of annualized asthma exacerbation rate (AER), St. George's Respiratory Questionnaire (SGRQ) total score, forced expiratory volume in one second (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), and Asthma Control Questionnaire\u20106 (ACQ\u20106). All\n                      <jats:italic>p<\/jats:italic>\n                      \u2010values were nominal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the ANDHI population (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0656), 23% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0153) participated in the NP substudy (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a096 benralizumab;\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a057 placebo). Patients were 50% female, with mean age of 53\u00a0years, had prior\u2010year AER\u00a0=\u00a03.3; mean pre\u2010bronchodilator FEV\n                      <jats:sub>1<\/jats:sub>\n                      \u00a0=\u00a055% predicted; and median blood eosinophil count\u00a0\u200b=\u00a0510\u00a0cells\/\u00b5l. For patients with high baseline SNOT\u201022 scores (&gt;30), benralizumab treatment improved symptoms of NP as measured by SNOT\u201022 from baseline to Week 24 compared with placebo (Week 24: \u221210.44 [\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.0176]). Percentage of responders to SNOT\u201022 was greater for benralizumab vs. placebo (71.3% vs. 45.5%;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.0036), and effect was enhanced for patients with high baseline SNOT\u201022 scores (&gt;30). A 69% reduction vs. placebo in annualized AER (0.77 vs. 2.47;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001) and greater clinically meaningful improvements from baseline in SGRQ total score (\u221216.7), FEV\n                      <jats:sub>1<\/jats:sub>\n                      (+0.32\u00a0L), and ACQ\u20106 (\u20130.88) were observed (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001). Benralizumab was well\u2010tolerated. Frequency of adverse events (AEs) was similar for benralizumab (76.0%) and placebo (73.7%) groups. Most common AEs (frequency \u22655%) reported at a greater frequency in benralizumab vs. placebo included headache, sinusitis, pyrexia, and influenza.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These substudy data from ANDHI demonstrated the efficacy profile of benralizumab for patients with severe, eosinophilic asthma and NP, with improvement in SNOT\u201022 and asthma outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/all.14902","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T10:49:59Z","timestamp":1620816599000},"page":"150-161","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis"],"prefix":"10.1111","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-2557","authenticated-orcid":false,"given":"Giorgio Walter","family":"Canonica","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University Milan Italy"},{"name":"IRCCS Humanitas Research Hospital, Personalized Medicine, Asthma and Allergy Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim W.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Respiratory Research Unit Nottingham NIHR BRC University of Nottingham, Nottingham City Hospital Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chanez","sequence":"additional","affiliation":[{"name":"Department of Respiratory CIC Nord INSERMINRAE C2VN Aix Marseille University Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-5789","authenticated-orcid":false,"given":"Francesco","family":"Menzella","sequence":"additional","affiliation":[{"name":"Pneumology Unit Azienda USL di Reggio Emilia\u2010IRCCS Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Louis","sequence":"additional","affiliation":[{"name":"University and CHU of Li\u00e8ge Li\u00e8ge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-8209","authenticated-orcid":false,"given":"Borja G.","family":"Cosio","sequence":"additional","affiliation":[{"name":"Hospital Son Espases\u2010IdISBa and Ciberes Palma de Mallorca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[{"name":"University of Michigan Medical Center Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Mohan","sequence":"additional","affiliation":[{"name":"East Carolina University Brody School of Medicine Greenville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Burden","sequence":"additional","affiliation":[{"name":"AstraZeneca Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garcia Gil","sequence":"additional","affiliation":[{"name":"AstraZeneca Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02309-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2019.12.006"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2018.06.006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22214"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112374"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01225.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.07.049"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhino09.095"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02709.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105947"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127228"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(77)90171-3"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2012.26.3792"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.010"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13875"},{"key":"e_1_2_9_18_1","first-page":"45","article-title":"Nasal polyps in patients with asthma: prevalence, impact, and management challenges","volume":"9","author":"Langdon C","year":"2016","journal-title":"J Asthma Allergy"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13048"},{"key":"e_1_2_9_20_1","first-page":"323","article-title":"Chronic rhinosinusitis exacerbations are differentially associated with lost productivity based on asthma status","volume":"56","author":"Phillips KM","year":"2018","journal-title":"Rhinology"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin17.029"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/014556130708600719"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0194599818773065"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12983"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13984"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21688"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2015.36.3866"},{"issue":"29","key":"e_1_2_9_28_1","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens WJ","year":"2020","journal-title":"Rhinology"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1945892420961964"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.12.001"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00910-y"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.11.005"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_2_9_34_1","unstructured":"Xolair\u00ae(omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies. Novartis. June 3 2019.https:\/\/novartis.gcs\u2010web.com\/Xolair\u2010omalizumab\u2010significantly\u2010reduced\u2010nasal\u2010polyps\u2010and\u2010congestion\u2010symptoms\u2010in\u2010adults\u2010with\u2010chronic\u2010rhinosinusitis\u2010with\u2010nasal\u2010polyps\u2010in\u2010two\u2010phase\u2010III\u2010studies. Accessed June 29 2020."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1912-62"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/1945892418814768"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100050"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.044"},{"issue":"989","key":"e_1_2_9_39_1","first-page":"e1","article-title":"Mepolizumab, a humanized anti\u2010IL\u20105 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert P","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin09.144"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.047"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin17.139"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.01.003"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.005"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.020"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703501"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30344-2"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1347091"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30343-0"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00936-2018"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30406-5"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S190221"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20906963"},{"key":"e_1_2_9_57_1","article-title":"Rapid effect of benralizumab for hypereosinophilia in a case of severe asthma with eosinophilic chronic rhinosinusitis","volume":"55","author":"Tsurumaki H","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"e_1_2_9_58_1","doi-asserted-by":"crossref","first-page":"e00388","DOI":"10.1002\/rcr2.388","article-title":"Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab","volume":"7","author":"Minami D","year":"2018","journal-title":"Respirol Case Rep"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(20)30414\u20108"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"e_1_2_9_61_1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4103\/njcp.njcp_429_17","article-title":"Is sino\u2010nasal outcome test\u201022 reliable for guiding chronic rhinosinusitis patients for endoscopic sinus surgery?","volume":"21","author":"Singla G","year":"2018","journal-title":"Niger J Clin Pract"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21917"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000544"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00024-2015"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21885"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/00016489.2018.1538567"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13720"},{"issue":"62","key":"e_1_2_9_68_1","first-page":"PA1125","article-title":"Dupilumab improves SNOT\u201022 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS\/NP) in LIBERTY ASTHMA QUEST","volume":"52","author":"Busse W","year":"2018","journal-title":"Eur Respir J"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.14902","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/all.14902","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.14902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:06:32Z","timestamp":1692723992000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.14902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/all.14902"],"URL":"https:\/\/doi.org\/10.1111\/all.14902","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"2020-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}